Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 2Congenital Abnormalities 2Small Cell Lung Carcinoma 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1

Interventions

Cytarabine 23Mitoxantrone 9Etoposide 8Idarubicin 5Filgrastim 5tipifarnib 4fludarabine phosphate 4Daunorubicin 4Cyclophosphamide 4Topotecan 3Sorafenib 3Clofarabine 3Bortezomib 3Azacitidine 3tanespimycin 2alvocidib 2Peripheral Blood Stem Cell Transplantation 2Imatinib Mesylate 2Granulocyte Colony-Stimulating Factor 2Everolimus 2Cladribine 2Carboplatin 2Busulfan 2Arsenic Trioxide 2venetoclax 1veliparib 1trebananib 1sargramostim 1romiplostim 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Monocytic, Acute × Podophyllotoxin × Clear all
NCT01127009 2015-08-13

Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

Case Comprehensive Cancer Center

Phase 1 Completed
3 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡